Clinical Trials Logo

Interstitial Lung Disease clinical trials

View clinical trials related to Interstitial Lung Disease.

Filter by:

NCT ID: NCT03901534 Recruiting - Clinical trials for Obstructive Sleep Apnea

Assessment of Continuous Positive Airway Pressure Therapy in IPF

ACT-IPF
Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether biomarkers of lung injury and remodeling are responsive to effective continuous positive airway pressure (CPAP) treatment in adults with idiopathic pulmonary fibrosis (IPF) and moderate-to-severe obstructive sleep apnea (OSA).

NCT ID: NCT03901196 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Multi-elemental Imaging of Lung Tissues With LIBS (Laser-induced Breakdown Spectroscopy)

MEDICO-LIBS
Start date: January 22, 2020
Phase:
Study type: Observational

Evaluate the feasibility of performing a multi-elemental imaging analysis of lung specimens from patients with ILDs, with an technology named LIBS (Laser Induced-Breakdown Spectroscopy)

NCT ID: NCT03824834 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Morphine to Maximize the Benefits of Exercise Training in COPD or ILD and Persistent Breathlessness

MorEx
Start date: August 6, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the role of low-dose immediate-release oral morphine as a novel adjunct pharmacotherapy to enable symptomatic adults with advanced chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD) to exercise at higher intensities for longer durations and maximize the psycho-physiological benefits of a supervised exercise training program. We hypothesize that, compared to placebo, exercise training with oral morphine will result in relatively greater improvements in exercise endurance time and intensity ratings of perceived breathlessness during constant-load cardiopulmonary cycle exercise testing (CPET) at 75% of peak power output (PPO).

NCT ID: NCT03814317 Recruiting - Clinical trials for Interstitial Lung Disease

Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension

SAPPHIRE
Start date: January 30, 2020
Phase: Phase 2
Study type: Interventional

This study aims to evaluate the efficacy and safety of inhaled treprostinil in subjects with sarcoidosis-associated interstitial lung disease and pulmonary hypertension.

NCT ID: NCT03770663 Recruiting - Clinical trials for Interstitial Lung Disease

Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease

CATR-PAT
Start date: February 5, 2021
Phase: Phase 3
Study type: Interventional

"Antisynthetase syndrome (ASS) is one of the most severe inflammatory myopathy (IM), due to pulmonary involvement (interstitial lung disease, ILD). Until now, the most commonly used immunosuppresive therapy in Europe is Cyclophosphamide followed by different immunosuppressive drugs as maintenance therapy, including Azathioprine (and so called " European Strategy "). In the USA however, the first-line immunosuppressive treatment is Tacrolimus (so called " American Strategy "). None of these two different strategies has ever been studied prospectively, and there is no clear comparison of short and long-term treatment efficacy and tolerance. Thus, there are yet no evidences helping the clinicians in the therapeutic management of patients with ASS-related ILD. The aim of this study is therefore to compare both strategies as first line treatments or in relapsing patients : CATR.PAT study is a 52 weeks, randomized, comparative, controlled, open-labeled, phase III, therapeutic clinical trial, comparing two treatment strategies."

NCT ID: NCT03726398 Recruiting - Clinical trials for Pulmonary Hypertension

CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH

CRUSADE
Start date: September 1, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Patients with interstitial lung disease (ILD) and scleroderma who develop pulmonary hypertension (PH) do not fit well into the current classification system and treatments for pulmonary hypertension. This study aims to better understand patients with ILD-PH and scleroderma and to determine if treatment with Macitentan is beneficial.

NCT ID: NCT03670576 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

It's Not JUST Idiopathic Pulmonary Fibrosis Study

INJUSTIS
Start date: November 11, 2018
Phase:
Study type: Observational

Study of progression of fibrosis in ILD

NCT ID: NCT03630211 Recruiting - Clinical trials for Pulmonary Hypertension

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

SSc
Start date: July 31, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect.

NCT ID: NCT03478826 Recruiting - Clinical trials for Interstitial Lung Disease

Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)

Start date: August 1, 2018
Phase:
Study type: Observational

To develop a repository of blood samples from patients with ILD to support future studies into the development of such biomarkers. Patients with pneumonia and healthy patients will also be recruited as a control group.

NCT ID: NCT03467880 Recruiting - Asthma Clinical Trials

Multicenter Study of Impulse Oscillometry in Chinese

Start date: September 2016
Phase: N/A
Study type: Observational [Patient Registry]

The purpose of this study is to establish the reference values of impulse oscillometry (IOS) in healthy Chinese, and compare the indices of IOS in patients with lung disease, such as chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease (ILD), and upper airway Obstruction (UAO).